The Absolute Effect / Oncology Evidence
Renal Cell Carcinoma Trial Evidence
RCC evidence organized around surgery, systemic adjuvant therapy, metastatic cytoreduction and stereotactic treatment of localized disease.
Featured evidence
- EORTC 30904 — partial versus radical nephrectomy.
- CARMENA — cytoreductive nephrectomy in metastatic renal cell carcinoma.
- KEYNOTE-564 — adjuvant pembrolizumab after nephrectomy.
- S-TRAC — adjuvant sunitinib after nephrectomy.
- CheckMate 914 — adjuvant nivolumab plus ipilimumab.
- FASTRACK II — stereotactic ablative radiotherapy for primary renal tumours.